Market/Novel Tech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on  MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.

A study from Johnson & Johnson Innovative Medicine, New Jersey, United States, report that patients with delayed genetic testing may incur significantly higher healthcare costs… Read More »Johnson & Johnson study reports the economic value of early genetic testing in inherited retinal dystrophies diagnosis.

A report in Retina Today, entitled, “A new perspective on the retina wage gap”, by Aidan Gilson, BS and Ron Adelman, MD, MPH, MBA, showed… Read More »A report from authors at the Yale School of Medicine suggest that disparities persist between female and male retina specialists.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).

Adverum Biotechnologies (NASDAQ: ADVM) has announced to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional… Read More »Advernum Biotechnologies (NASDAQ: ADVM) has raised $127.5 million to progress gene therapy pipeline.